What is the history of Russell Silver Syndrome?

Russell Silver Syndrome, also known as Silver-Russell syndrome, was first independently described in 1953 and 1954 by pediatricians Henry Silver and H.K. Silver, and later by Silver and colleagues. It is a rare genetic disorder characterized by intrauterine growth restriction (IUGR), postnatal growth failure, and distinctive physical features, now understood to be caused by epigenetic changes in approximately 60% of cases.

When and how was Russell Silver Syndrome first described?

The history of Russell Silver Syndrome began in the early 1950s. In 1953, Alexander Russell described five children with primordial dwarfism and craniofacial characteristics. Shortly thereafter, in 1954, Henry Silver described two children with similar growth patterns and congenital asymmetry. The medical community eventually merged these observations into the eponym Russell Silver Syndrome, recognizing that these two physicians were documenting the same spectrum of clinical findings.

How has the understanding of Russell Silver Syndrome evolved?

For decades, Russell Silver Syndrome was diagnosed strictly through clinical observation, focusing on the "classic" triad of low birth weight, a triangular face, and body asymmetry. The evolution of molecular genetics in the 1990s revolutionized the field, shifting the focus from purely clinical signs to underlying epigenetic mechanisms. We now know that Russell Silver Syndrome is primarily caused by:

• Loss of methylation on chromosome 11p15.5 (found in roughly 50% of cases).


• Maternal uniparental disomy of chromosome 7 (found in roughly 10% of cases).


• A remaining 40% of cases where the underlying genetic cause remains unidentified by current standard testing.

What milestones have shaped the treatment of Russell Silver Syndrome?

Historically, children with Russell Silver Syndrome faced significant challenges regarding stature and metabolic health. A major milestone occurred in the early 2000s with the FDA approval of recombinant human growth hormone (GH) therapy for children with growth failure born small for gestational age (SGA). This treatment has significantly improved the final adult height and metabolic outcomes for many living with Russell Silver Syndrome.

The evolution of patient advocacy

Early medical literature often focused on the "dwarfism" aspect of Russell Silver Syndrome, which sometimes overshadowed the complex multisystem care required. Today, the 263 members of our DiseaseMaps.org community highlight the importance of patient-led advocacy, which has pushed for earlier diagnosis and multidisciplinary care, including endocrinology, nutrition, and speech therapy.

Next steps

• Consult a clinical geneticist to discuss the latest methylation testing protocols.


• Work with a pediatric endocrinologist to assess candidacy for growth hormone therapy.


• Join the DiseaseMaps.org community to connect with others sharing their experiences with Russell Silver Syndrome.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Russell-Silver syndrome.


• Orphanet: Silver-Russell syndrome (ORPHA:3260).


• OMIM (Online Mendelian Inheritance in Man): Silver-Russell syndrome (Entry #180860).


• The MAGIC Foundation: Resources for Russell-Silver Syndrome.